137862-53-4 valsartan

Pwopriyete

Aparans blan pou poud tan
Pwen k ap fonn: 116-117 degre
Pwen bouyi: 684.9 ± 65. 0 degre
Dansite 1.212 ± 0. 06 g/cm3
Vapè presyon 0-0 PA nan 20-25 degre
Depo tanperati. 2-8 degre
solubility DMSO: pi gran pase oswa egal a 20mg/ml
PKA3.56 ± 0. 10
Aktivite optik []/d -55 pou -70 degre, C=1 nan methanol
Dlo solubility 84.99mg/L (25 ºC)

 

Aplikasyon:

Valsartan se yon anjyotansen II reseptè antagonist antiipèrtansif dwòg ki aji yo bloke tip I (AT1) reseptè a nan anjyotansen II, ogmante nivo plasma nan anjyotansen II, estimile reseptè a ki pa fèmen AT2, ak debat efè a nan AT1 reseptè, kidonk reyalize efè a nan dilatasyon san ak bese san yo. Nan peyi Etazini, Valsartan se yon medikaman ki itilize pou trete tansyon wo, ensifizans kadyak konjestif, ak afiche enfaktis myokad. Valsartan Devin devlope ak pwodwi pa konpayi Swis Ciba Geigy jwenn rive ki enpòtan nan Etazini yo ak Ewòp an 1995 ak 1996, respektivman. Li te premye te lanse nan Almay an Jiyè 1996 e li te depi yo te lanse nan Ewòp, Etazini yo, ak Japon. CIBA Cargill ak Sandoz fusionné pou fòme Novartis an 1996. Valsartan gen karakteristik ki dire lontan ak ki estab tansyon bese efè, ak minim efè segondè toksik.

 

Sinonim:

sapat talsartan

137862-53-4

Diovan

CGP -48933

(S) -2- (n-((2 '-(1h-tetrazol -5- yl)-[1,1'-biphenyl] -4- yl) Pentanamido) -3- asid methylbutanoicoic asidoik)

Prexartan

Valzaar

Valtan

N- (p- (o -1 h-tetrazol -5- ylphenyl) benzyl) -n-Valeryl-L-Valine

(2S)-3-methyl-2-[pentanoyl-[[{{4}[}2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic asid

L-valine, n-(1- oxopentyl) -n-[[2 '-(2H-tetrazol -5- yl) [1,1'-biphenyl] -4- yl] methyl]-

80m03yxj7i

Chebi: 9927

L-Valsartan

137863-60-6

L-valine, n-(1- oxopentyl) -n-((2 '-(1H-tetrazol -5- yl) (1,1'-biphenyl) -4- yl) methyl)-

Dafiro eleman valsartan

Copalia eleman valsartan

 

 

Baj popilè: 137862-53-4 Valsartan, Lachin 137862-53-4 Valsartan Konpayi fabrikasyon, Swèd